je.st
news
Tag: hepatitis
Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
2016-03-30 13:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Presentations Include Results from Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the companys broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: international
development
present
programs
Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
2016-03-25 15:53:27| Biotech - Topix.net
The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni.
Tags: pay
million
drug
ordered
Jury finds for Merck in hepatitis drug fight with Gilead
2016-03-23 00:19:12| Biotech - Topix.net
A federal jury in California has ruled in favor of drugmaker Merck in a high-stakes lawsuit against rival Gilead Sciences concerning patents for lucrative new drugs for hepatitis C. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead's sofosbuvir infringes on those patents. Sofosbuvir is the active ingredient in Gilead's Sovaldi and a component of its Harvoni, which together brought in $19.1 billion last year.
Baby boomers warned to be on alert for hepatitis C
2016-03-09 23:22:33| Biotech - Topix.net
Attention, baby boomers. You are especially susceptible to a silent killer. One that may have hidden dormant and undetected in your system for decades, until it suddenly announces itself to the dreadful tune of liver cancer or cirrhosis.
Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic Hepatitis C Infection
2016-03-09 22:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, applauds the U.S. Department of Veterans Affairs (VA) for broadening access to treatment for Veterans with chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
access
department
treatment
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »